(VIR) – Hot FDA News
-
Vir Biotechnology Inc. (VIR) to Resume Trading at 8:30 a.m. After Phase 2 Study Fails
-
FDA Revises EMA For Vir (VIR) and GlaxoSmithKline's Sotrovimab Due to Omicron BA.2 Subvariant
-
-
-
-
-
-
-
-
-
-
Back to VIR Stock Lookup